Future studies should focus on specific NF-κB activators or inhibitors, explore interactions among various signaling pathways, and utilize immunocompetent mouse models and patient-derived organoid systems to better mimic the tumor microenvironment and immune responses in patients. This evidence concerns the gene NFKB1 and neoplasm.